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INTRODUCTION 
 
                The invention of LASER was one of the most brilliant inventions 
of the 20th century. LASER is an acronym for ‘Light Amplification by the 
Stimulated Emission of Radiation’. Its application in cutaneous surgery has 
evolved to a great extent in the last three decades.  
 
               LASERs have been in use for the treatment of a variety of 
cutaneous conditions like pigmented lesions, vascular anomalies, tattoos, 
hirsutism, keloids and hypertrophic scars, and also for skin resurfacing. 
 
                Keloids are aberrant responses to cutaneous insult characterised 
by hyperproliferation of dermal collagen.1 They often present as a cosmetic 
concern and also cause remarkable pain and pruritus. Treatment of such 
lesions is a challenge as many modalities have been tried but none with 
significant improvement. Conventional methods for the treatment of 
keloids include surgical excision, dermabrasion, grafting, radiation, 
pressure therapy, silicone gel sheeting and intralesional corticosteroids.2,3 
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LASERs have been used with variable success in the treatment of 
keloids. Nd:YAG (Neodymium-doped yttrium aluminium garnet) and CO2 
lasers were earlier used with promising results but recent reports have not 
proven their long term efficacy.4 
 
However, in the last 20 years, 585-nm pulsed dye laser has been very 
effectively used to reduce the scar erythema, size and associated 
symptoms. 
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AIMS AND OBJECTIVES 
 
To assess the efficacy of fractional CO2, long pulse Nd:YAG and 
pulsed dye LASER in the management of keloids. 
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REVIEW OF LITERATURE 
 
LASERs have gained considerable attention from the dermatologic 
and plastic surgery communities in recent years. The term ‘LASER’ was 
coined in 1957 by Gordon Gould who is known as the ‘pioneer of lasers’.5 
It is an acronym for ‘Light Amplification by Stimulated Emission of 
Radiation’. 
 
 
History of Lasers 
 
The phenomenon of stimulated light emission was put forward by 
Einstein in 1917. He proposed that a photon of electromagnetic energy 
could stimulate the emission of another identical photon from atoms or 
molecules that are in an excited state.6 Einstein’s magnanimous work on 
Richard Gordon Gould 
17 July, 1920 – 16 September 2005 
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laser was published in an article titled‘Zur Quantentheorie der Strahlung’ 
which means the ‘Quantum Theory of Radiation’. 
 
Theodore Maiman, a physicist from California developed the first 
laser in 1959 using a ruby crystal to produce red light with a wavelength 
of 694nm.7Dr Leon Goldman pioneered the utility of lasers for 
dermatological applications by promoting ruby laser therapy for avariety 
of cutaneous pathologies in 1963.8-10
 
The Argon laser which emitted blue-green light with a wavelength 
of 488/514 nm, was developed in 1962 and was mainly used for the 
treatment of vascular lesions. Later, in 1964, the carbondioxide (CO2) laser 
which produced infrared light with a wavelength of 10,600 nm was 
developed. This was primarily used for tissue vapourization and 
destruction of a variety of cutaneous lesions.11 
Theodore Harold Maiman 
11 July, 1927 – 5 May, 2007 
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There was a revolution in the field of cutaneous laser surgery in the 
early 80s when the theory of ‘selective photothermolysis’ was proposed 
by Anderson and Parrish.12 
 
The application of this concept of ‘selective photothermolysis’ 
allowed specific and controlled destruction of a target with a very little 
damage to the surrounding normal tissue. To achieve this, a specific 
wavelength that is absorbed by the target is selected and the duration of 
exposure of the tissue, i.e. the pulse duration must be kept shorter than 
‘the time taken by the targeted tissue to dissipate half the absorbed heat’, 
which is known as its ‘thermal relaxation time’. 
 
These targets that absorb laser of a particular wavelength are known 
as ‘chromophores’ and they do so when their absorption spectrum 
matches with the wavelength of that particular laser. Some of the common 
‘chromophores’ in the human skin are haemoglobin, melanin and water. 
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The absorption of different chromophores and the wavelengths of 
LASERs13 
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Principles of Lasers 
 
LASER light has certain unique properties due to which it has the desired 
therapeutic effects.  
1. Monochromatic, which means that the emitted light has a distinct, 
single wavelength.  
2. Coherence, which means that the laser travels in phase with peaks 
and troughs of the light all aligned. 
3. Collimation, which indicates non-divergent, parallel propagation of 
a narrow and intense beam of light. 
 
According to the ‘Grotthus-Draper law’, which is the primary ‘law of 
photobiology’, light has to be absorbed by the tissue, in order to cause a 
clinical effect. And, the reflected, transmitted or scattered light does not 
affect the tissue. 
 
After the absorption of laser by the target, 3 possible effects can occur: 
1. Photothermal effect: This occurs when a chromophore absorbs 
energy of the corresponding wavelength and gets destroyed as a 
result of conversion of the absorbed energy into heat. 
2. Photochemical effect: Photo-sensitizer – like reactions 
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3. Photomechanical effect: This occurs as a result of acoustic waves 
due to extreme thermal expansion. 
 
Laser Parameters 
• Laser energy is measured in joules (J) 
• The amount of energy delivered per unit area (J/cm2) is called 
Fluence. It is also known as energy density. 
• Power(measured in watts)is the rate at which energy is delivered. 
(1 watt = 1 J/sec) 
• The wavelength is determined by the lasing ‘medium’ of each laser. 
It is the active medium contained in an optical cavity through which 
the laser light passes. 
• It is either a gas (argon or CO2), liquid (dye like rhodamine, 
fluorescein, malachite green etc.), or a solid (ruby, alexandrite, 
neodymium : yttrium-aluminium-garnet crystal) 
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Modes of Operation 
 
 Continuous wave: Emission of a constant beam of light. The 
exposure durations are long and may lead to non-selective tissue 
injury. Ex: Continuous wave CO2 laser, Argon lasers (old). 
 
 Quasi-Continuous wave: Shuttering of the continuous wave of 
beam into short segments, thus causing interrupted emission of 
constant energy. Ex: KTP, copper bromide, argon-pumped tunable 
dye(APTD), krypton lasers etc. 
 
 Pulsed wave: Emission of high energy laser with ultrashort pulse 
durations. These may be long-pulsed, ex: PDL, or short-pulsed, ex: 
Q-switched ruby, alexandrite or Nd:YAG lasers. 
 
Superpulsed: Specifically used for carbondioxide lasers that 
produce very short pulses at a particular repetition, thereby, reducing 
the thermal damage of the surrounding tissue. 
 
 ‘Quality-switched’ (Q-switched) – emit high energy pulses with 
very short pulse durations. 
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LASERs in Dermatology 
 
There has been a magnificient advancement in the field of lasers in 
dermatology over the last three decades. It is quite well-known that this 
revolution has changed the face of aesthetics and dermato-medicine. 
  
Lasers have been in use for a variety of skin conditions like 
pigmented lesions, vascular anomalies, tattoos, hirsutism, keloids and 
hypertrophic scars, and also for skin resurfacing. 
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Basic lasers used in dermatology 
 
Type of LASER 
 
Wavelength 
 
Chromophore 
 
Use 
 
Pulsed dye 
 
585 nm / 595 
nm 
 
Oxyhaemoglobin 
 
Vascular 
lesions, 
Keloids 
 
Nd:YAG (freq. 
doubled) 
 
532 nm 
 
Pigment 
Superficial 
pigment, 
tattoos (red, 
orange, 
yellow) 
 
Q-switched 
Ruby 
 
694 nm 
 
Pigment 
Tattoos 
(blue, black, 
green) 
Ruby (Long 
pulsed) 
 
694 nm 
 
Melanin 
 
Epilation 
 
Alexandrite (Q-
switched) 
 
755 nm 
 
Pigment 
Tattoos 
(blue, black, 
green) 
Long pulsed 
alexandrite 
 
755 nm 
 
Melanin 
 
Epilation 
 
Q-switched 
Nd:YAG 
 
1064 nm 
 
Pigment 
 
Tattoos 
(black, blue) 
 
Long pulsed 
Nd:YAG 
 
1064 nm 
 
Melanin 
 
Epilation 
 
 
 
Erbium:YAG 
 
 
 
2940 nm 
 
 
 
Water 
 
Superficial 
skin 
resurfacing, 
epidermal 
lesions 
 
 
 
Carbondioxide 
 
 
 
10,600 nm 
 
 
 
Water 
Skin 
resurfacing, 
epidermal 
and dermal 
lesions 
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KELOIDS 
 
     Keloids and hypertrophic scars occur as a result of abundant 
deposition of collagen, the cause of which is unclear. They give rise to both 
functional and aesthetic distress to the patient and have always been a 
therapeutic challenge, despite the innumerable modalities of treatment. It 
is very important to define the most appropriate therapy which is not 
possible without a clear knowledge of the pathogenesis and the clinical 
characteristics of the scar. 
 
‘Keloid’ was derived from the greek word ‘chele’ which means crab 
claw by Alibert, in order to demonstrate its claw-like extension into the 
surrounding tissue.14 
              Keloidal scars may cause symptoms like pain, pruritus, restriction 
of movements and also aesthetic disfigurement leading to a significant 
amount of morbidity. 
 
However, keloids differ from hypertrophic scars clinically in many 
aspects. Hypertrophic scars are confined to the original wound and develop 
within weeks after injury, unlike keloids, which occur months to years after 
14 
 
the skin insult and surpass its boundaries. Keloids do not tend to regress 
but hypertrophic scars show remission as the time progresses.15,16  Keloids 
have greater chances of recurrence and are more recalcitrant to treatment 
when compared to hypertrophic scars.17 
 
Keloids are seen in predisposed individuals after injuries including 
surgery, burns, tattooing, piercing, abrasions, lacerations and inflammatory 
conditions like folliculitis, acne, chicken pox etc.18,19  Very rarely, they 
show a spontaneous development.20 
 
They are more common in individuals with darker skin but are found 
with similar frequency in both males and females.21,22 They may start at 
any age, however, are more common between the 2nd and 4th decades of 
life.,16,23 
 
Clinically, they are soft or firm or doughy in texture and may vary 
in diameter from a few millimetres to several centimetres. They are 
predominantly seen over the chest, upper back and arms, shoulders, face, 
ear lobes etc., cause of which could be the high skin tension of these 
areas.19 
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Along with the aesthetic disfigurement that they cause, they often 
also result in pruritus, pain, super added infection, ulceration, tightening 
thereby, leading to restriction of movement.24,25 
 
Wound Healing 
 
Normal wound repair is a critical process that involves the balanced 
and meticulously timed activity of various inflammatory, connective 
tissue, vascular and epithelial cells. It consists of overlapping phases of 
hemostasis, inflammation, proliferation and remodelling. 
 
On injury of skin, there is a release of chemotactic and vasoactive 
factors that lead to the migration of inflammatory cells. Several cytokines 
that play a crucial role in healing by modifying the wound environment are 
released by the macrophages. In the next phase, fibroblasts aggregate in the 
site of injury and produce a structural framework by the deposition of type 
I and type III collagen.  
 
Normally, in the stage of maturation, there is a decreased hyperemia 
and angiogenesis along with concurrent synthesis and degradation of 
collagen resulting in diminished nodularity and thereby, scar flattening.2 
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Pathophysiology of Keloid formation 
 
   Although the proper pathophysiologic mechanism in the formation 
of hypertrophic scars and keloids is not clear, many authors have published 
their meticulous work on the microcellular mechanisms involving the 
development of scars. It has been investigated that the activity of 
fibroblasts, various growth factors, components of extracellular matrix, 
cytokines and immune response portray the cellular basis of exaggerated 
fibrogenesis leading to the formation of a keloid. 
 
 The keloid has fibroblasts that differ in properties from those present 
in the normal skin. Most importantly, they have an aberrant response to 
injury and a higher ability of proliferation, producing excessive amount of 
collagen (majorly type I collagen), proteoglycans, elastin and 
fibronectin.26-32 
 
 On the other hand the fibroblasts of hypertrophic scars show a 
normal response to the growth factors and delineate a normal increase in 
the production of collagen.33 
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 Growth factors that play a pivotal role in the wound healing cascade 
include: 
1. TGF β – Transforming growth factor – β 
2. Platelet derived growth factor 
3. Insulin – like growth factor (IGF) 
Function of TGF–β  
The platelets release the transforming growth factor – β that urges 
the macrophages and monocytes to produce extracellular matrix proteins. 
It has been proved by many authors that there is a precise association 
between the increased synthesis of collagen by the fibroblasts of keloids 
and the TGF-β.28,33,34-36 
Function of IGF  
Expression of type 1 and type 3 procollagen is exponentially 
increased by the insulin-like growth factor-137 and its receptor (IGF-1 
receptor) is abundantly seen in the fibroblasts of keloids.38 
 
 As proposed by several scientists, erratic levels of different 
cytokines like interleukin-6, 13 and 15 have a crucial role in the 
development of keloids.38-40 
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  Hyaluronic acid, which is an extracellular matrix protein, binds to 
the receptors located on the surface of fibroblasts, and is said to cause 
localisation of TGF-β to the fibroblasts, thereby stimulating the synthesis 
of collagen.  
 
However, there has always been a conflict of opinion in the levels of 
hyaluronic acid, as few researchers found increased synthesis of hyaluronic 
acid in the fibroblasts of keloids in comparison with those of the normal 
skin, while some have demonstrated decreased production in the keloidal 
dermis.42,43 
 
 A proportion of authors proposed a relationship with the expression 
of HLA class II molecules,44,45 while some demonstrated elevated levels of 
immunoglobulins.46 
 
Other pathogenic hypotheses include: 
1. Hypoxia of the tissue47 
2. Changes in the composition of fatty acids of fibroblasts48 
3. Increased production of nitric acid in the wound repair49 
4. Possibility of immune response to sebum50 
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                                          A keloid on the chest 
 
Histopathology of Keloid 
It is very difficult to differentiate a keloid from hypertrophic scar 
histopathologically. Normal skin shows distinguishable collagen bundles 
running parallel to the epidermis.  
 
They are flattened, less distinct and are arranged in a wavy pattern 
with a parallel orientation to the epithelium in hypertrophic scars. 
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    However, in a keloid, the bundles of collagen are non-existent 
virtually and the fibres are arranged loosely in indistinctly oriented sheets. 
 
   Hypertrophic scars show nodular structures containing collagen and 
fibroblasts, which are however, absent in normal skin and most of the 
keloids. 
 
Treatment of Keloids 
 
As it is a well-known fact that the treatment of keloids has been a 
therapeutic challenge, despite good understanding of the wound repair 
mechanism and expertise in the field of medicine, it is of utmost 
importance to remember that prevention of keloids is the best possible 
treatment available. 
 
Therefore, it is essential to counsel patients who are predisposed to 
develop thick scarring to be careful not to injure themselves and to avoid 
unnecessary surgeries or body piercings. 
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However, if a keloid develops, there are many ways of therapy to 
choose from, depending on the requirements of the patient, while keeping 
the socio-economic status in mind, although, there is no globally accepted 
treatment modality that can permanently cause regression of a keloid.  
 
Various treatment options 
a) Surgery 
b) Radiation 
c) Pressure/Compression therapy or garments 
d) Cryotherapy 
e) Silicon get sheets 
f) Intralesional corticosteroids 
g) Interferon alpha 
h) 5-Fluorouracil 
i) Intralesional bleomycin 
j) LASER 
        -  Carbondioxide 
         - Erbium:YAG / Nd:YAG  
         - Pulsed dye laser 
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Surgery 
All the surgically excised keloids usually recur as the newly created 
wound is affected by similar biological and mechanical forces of the 
original scar. 
 
It has been reported that the recurrence rate may range upto 100%, 
if excision is chosen as an individual modality (or monotherapy).21,51,52 
 
It is also believed that the keloids that have reappeared post-surgery 
tend to recur if surgical excision is performed again.18,53 
 
Another procedure called ‘core extirpation’ is the excision of the 
fibrous core keeping the capsule intact, in continuation with the normal 
skin which acts as a flap. 
 
Radiation 
It is usually used in combination with surgical excision and not very 
frequently used as monotherapy. A dose of approximately 1500 Gy are 
delivered (in fractions) within 10 days after surgery. It acts by inhibition of 
angiogenesis and inhibition of the proliferation of fibroblasts during the 
process of wound repair. 
23 
 
Pressure/Compression therapy 
This modality of treatment was first performed in the 60s. It is 
hypothesised that the continuous delivery of pressure results in tissue 
ischemia, thereby hindering the metabolism of the tissue and increasing the 
activity of the collagenase.54,55,56 
 
 There is another theory which states that the release of 
metalloproteinase / PG E2 due to the pressure therapy causes remodelling 
of the extracellular matrix, thereby softening the keloid.  
 
Despite being proved to be effective in several studies, there are 
many demerits of pressure therapy. The most uncomfortable part is the 
necessity to wear it for more than 24 weeks for about 18 hours a day. Older 
scars do not respond well and also bringing about the required pressure of 
about 24-40 mm Hg is quite challenging in areas of joints where the skin 
is mobile. 
 
 This always results in very low patient compliance as it is 
uncomfortable and irritating. 
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Cryotherapy 
It is employed either individually or in combination with other 
modalities of treatment for the therapy of keloids and hypertrophic scars. 
The mechanism by which it causes the regression of the scar is reported to 
be due to the freezing-induced ischemia of tissue caused by damage of the 
microvasculature. 
Freezing 
 
Vascular damage 
 
Stasis of microcirculation 
 
Hypoxia 
 
Necrosis 
Each keloid is treated with 2-3 freeze-thaw cycles, each of 30 
seconds. 
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It is not very desirable in patients with darker shades of skin because 
it may result in permanent hypopigmentation as the melanocytes are 
sensitive to cold. 
 
Silicon Gel Sheeting 
 
Topical silicon gel sheeting has been proved to relieve the most 
notorious symptom of keloids which is pruritus in a number of studies and 
has also showed significant softening of keloids and hypertrophic scars. 
These dressings are kept over the keloids in contact and then secured with 
a tape for about 12 hours each day.  
 
    It acts by the modification of the fibroblasts caused due to the 
hydration provided by the dressing.57 
Hydration 
 
Fibroblast modification 
 
Softening of keloid 
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        These are used as preventive strategy post-surgeries, after the 
healing of the operative wound. These are the most accepted treatment 
option among all the non-invasive therapies as there are no significant side 
effects.  
 
Intralesional Corticosteroids 
It has been the most accepted therapy and considered the first line of 
treatment for hypertrophic scars and keloids. Several studies have reported 
the softening of the texture, flattening of the lesion as well as improvement 
in the symptoms such a pruritus and tightening after being given 
intralesional triamcinolone acetonide.58,59,60 
 
 It has been observed that the rate of recurrence is significantly 
decreased when this is used in combination with surgical excision. 
 
 The most efficiently and commonly used intralesional 
corticosteroid, triamcinolone acetonide is either given individually or in 
combination with a local anaesthetic. When diluted with lidocaine, it has 
been proved to reduce the pain and discomfort caused due to the injection. 
Corticosteroids act by inhibiting the synthesis of collagen and also have an 
anti-inflammatory effect. 
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Decreased gene expression 
 
Collagen synthesis suppression 
 
Keloid regression 
 
 Although this treatment option is very effective and widely 
accepted, several adverse effects that make it a ‘not very desired procedure’ 
include: 
1. Pain during the injection 
2. Atrophy 
3. Telengiectasia 
4. Hypopigmentation 
5. Depigmentation 
 
Also, it is sometimes very difficult to push the drug into the fibrous 
mass which can be made easy by either injecting hyaluronidase or 
delivering cryotherapy or by using pulsed dye laser. 
 
28 
 
Interferon Alpha 
Interferon alpha-2b was first used by Duncan and Berman61 as it had 
a anti-proliferative effect. They treated a keloid with 2 doses of interferon 
alpha-2b 1.5 million International Units, with an interval of 4 days and 
have found that the keloid reduced to half the original size. 
     
IFN acts by reducing the synthesis of type 3 and type 1 collagen from 
the fibroblasts, thus proving its anti proliferative property. 
 
5-Fluorouracil 
5-Fluorouracil is a pyrimidine analogue with a anti-metabolite 
activity. Fitzpatrick demonstrated the efficacy of this drug with and 
without steroid in the treatment of scars and keloids.62 It acts by inhibiting 
the proliferation of fibroblasts. Initially, the injections need to be given 
frequently, about 1 to 3 per week, followed by longer intervals of four to 
six weeks between 2 doses. 
 
Injections need to be given only in the hard or indurated area till a 
mild blanching is noticed. As these are very painful, they can be given in 
combination with triamcinolone acetonide or after administration of a local 
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anaesthetic. Combining a corticosteroid reduces the inflammation in 
addition to relieving the pain. 
5-FU 
 
Inhibition of fibroblast proliferation 
 
Decreases scarring 
 
Intralesional Bleomycin 
Bleomycin has shown to flatten keloids when given at a dose of 1.5 
International Units/ml intralesionally.63 
 
Other agents used for the treatment of keloids 
a) Imiquimod (Local immunomodulatory) 
b) Intralesional Verapamil 
It is said that it acts by the inhibition of endothelial growth factor 
and interleukin - 6 
c) Calcium antagonists 
d) Tamoxifen 
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e) Tretinoin 
f) Tacrolimus 
g) Tranilast 
h) Zinc 
i) Vitamin E 
j) Pentoxifylline 
k) Colchicine 
l) Calcium antagonists 
 
LASERs for Keloids 
Apfelberg et al.64, first reported the use of lasers on keloids by 
irradiation with carbondioxide and argon lasers in 13 patients out of whom, 
only 1 patient showed improvement.  
 
Later after multiple experiments with argon and CO2, Nd:YAG and 
PDL were evaluated for the treatment of keloids, with variable outcomes. 
However, pulsed dye laser, later showed promising results. Several authors 
suggested that other therapeutic modalities like intralesional steroids, 
silicone gel sheets or pressure therapy should be advocated in combination 
with lasers.19 
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Pulsed dye laser was reported to significantly control pruritus in both 
keloids and hypertrophic scars. 
 
Possible mechanism by which LASERs control pruritus: 
Modification in 
a) Neuropeptide Y 
b) Vasoactive intestinal peptide 
c) Substance P 
d) CGRP (calcitonin gene-related peptide) 
 Allison et al.65 reported a diminished number of mast cells 
as another mechanism of pruritus reduction which was however, 
contradictory to the theory put forth by Alster and Williams66 who 
suggested a rise in the number of mast cells after treatment with laser. 
 
Lasers have been reported to show an improvement in the texture of 
the skin, the cause of which is suggested be the result of remodelling of 
collagen. 
 
Also, improvement in the pain, tightness and erythema has been 
reported after Laser therapy.  
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Adverse effects of Laser treatment 
 
1. Post-operative purpura: 
It is a common adverse effect of PDL and may persist for upto 1 
week after the procedure.           
2. Hyperpigmentation: 
This may be due to the heat injury of the epidermis resulting from 
the absorption of melanin. It is more frequent in dark skinned 
patients. 
3. Transient hyperpigmentation / hypopigmentation 
4. Blistering 
 
Mechanisms of action 
 
The exact mechanism by which Lasers cause scar regression is not 
known, however, the available theories are based on the phenomenon of 
‘selective photothermolysis’. 
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Light energy from a vascular laser (PDL) 
 
Absorbed by haemoglobin, heat generation 
 
Coagulation necrosis 
 
Hypoperfusion & hypoxia, resulting in neocollagenesis 
 
Heating of collagen fiber + Breakage of disulphide bonds 
 
Realignment of collagen fibres 
 
Decreased fibroblast proliferation and reduced deposition of type 3 
collagen 
 
Another possible mechanism is the apoptosis induction along with 
ERK (extracellular signal-regulated kinase) upregulation and activity of 
p38 MAP (mitogen-activated protein) kinase.As it is quite evident that the 
transforming growth factor – beta 1 (TGF- β1) is associated with 
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modulation and induction of collagen formation, PDL causes regression of 
keloids by downregulating TGF-β1. 
 
Nowak et al.67 reported that the superpulsed carbondioxide laser 
causes the release of bFGF (basic fibroblast growth factor) and inhibition 
of TGF-β1 release in keloids. 
 
Paquet et al.68 have shown that induction of anoxia by capillary 
destruction using lasers alters synthesis of collagen by fibroblasts and 
degradation mediated by the release of metalloproteinase. 
 
Wavelengths of  LASERs used for hypertrophic scars and keloids69 
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Factors influencing the outcome of LASER treatment 
a) Wavelength 
b) Fluence 
c) Spot size 
d) Scar location 
e) Scar duration 
f) Combination therapy 
 
Wavelength 
Selection of the precise wavelength is the most crucial factor that 
determines the outcome of the treatment. Several lasers with different 
wavelengthsstarting from 488 to 1064nm have been analysed for the 
treatment of keloids and hypertrophic scars. The pulsed dye laser that has 
a wavelength of 585 nm has been demonstrated to be the most efficacious 
laser influencing the scar growth, although, there are very few studies 
proving the same. 
 
 It is hypothesised that the mechanism of action by which lasers cause 
regression of keloidal scars is by targeting the haemoglobin, and therefore 
the lasers with a wavelength closer to the absorption peak of 
oxyhaemoglobin (542 nm) are thought to be the most successful. 
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These kind of lasers do not have a deeper penetration and are hence 
are not useful for deeper vessels.    
 
Carbondioxide laser which has a wavelength of 10,600nm has not 
given satisfactory results in the scar ablation, with 39-92% rates of 
recurrence.71-75 
 
 The Nd:YAG laser which has a wavelength of 1064nm has proved 
to specifically supress the production of collagen in the cultures of 
fiboblasts.76 
 
 A recent study on frequency doubled Nd:YAG (532 nm) laser 
demonstrated significant success when compared to 585 nm – PDL in the 
treatment of ‘pigmented hypertrophic scars’. This wavelength of Nd:YAG 
laser is very close to the oxyhaemoglobin absorption peak which is 542 
nm, making this a better option for the treatment of keloids and 
hypertrophic scars. 
 
 The Erb:YAG laser with a wavelength of 2940 nm has been tried in 
adjunction with the carbondioxide laser by Cheng et al. in invitro studies 
in which they noticed a rise in the basic fibroblast growth factor (bFGF) 
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and a fall in the levels of  transforming growth factor – beta 1 (TGF-β1) in 
the cultured fibroblasts of keloids. 
 
 The argon laser with a wavelength of 488 nm causes shrinkage of 
the collagen by localised thermal induction, thereby helping in scar 
regression and is known to give rise to a higher rate of recurrence ranging 
from 45-93 %.73,78,79 
 
 Carbondioxide laser in combination either with Er:YAG or pulsed 
dye laser proved to show satisfactory results when compared to 
monotherapy with either of the lasers. 
 
Fluence 
It is also very important to choose the appropriate fluence as a pulsed 
dye laser in low fluence has shown to cause an increase in the rate of 
production of procollagen and the same laser in high fluence was thought 
to cause focal thermal coagulation leading to a greater magnitude of 
adverse effects.80,81 
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The optimal fluence that should be used for the treatment of scars 
ranges from 3.5 J/cm2 – 7.5 J/cm2.82-86 
 
A few investigators have suggested that a laser at higher fluence 
results in a better scar response, studies have not proved any significant 
dissimilarities in the outcome of the treatment. 
 
Spot Size 
It is another factor that needs to be kept in mind before starting the 
procedure as it plays an important role in the treatment outcome. 
 
 It is suggested to select a smaller spot size for a laser with higher 
fluence and a larger spot size for patients with dark skin to intensify the 
degree of penetration and to achieve better results. 
 
Scar location 
 Although there are no globally accepted theories regarding the 
relation between the location of the scar and the efficacy of the treatment, 
Nouri et al. observed that scars on the face, shoulders and arms showed a 
good response when compared to those on the chest.87 
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Dierickx et al. also demonstrated a good outcome for scars over the 
face.83 
 
 But, Alster and Nanni88 proposed no association between location of 
the scar and treatment outcome. 
 
Scar Duration 
 
 It is thought that age of a scars plays a role in the response to 
treatment as differently aged scars respond in different ways to the same 
therapy. 
 
 Some researchers have showed that scars which are less than 1 year 
old can be treated easily when compared to older scars, but the other set of 
authors disagree with the same. 
 
Combination Therapy 
Adjunctive use of intralesional corticosteroids, 5-fluorouracil and/or 
hydroquinone has been proved to be very helpful in the treatment of 
keloids.89 
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Combination therapy of PDL with intralesional triamcinolone 
acetonide (10-20mg) brought about a very significant improvement of 
pruritus, although, there was no sufficient regression of scar. It was 
reported that higher conc. Of steroids would have given a better outcome, 
although, with a higher risk of adverse events like telangiectasia and 
atrophy of skin. 
 
Hydroquinones proved to be efficacious in enhancing the desired 
result by decreasing the epidermal pigmentation.82 
 
 Even after 3 decades of progress in the field of laser therapy for 
keloids and hypertrophic scars, treatment of keloids still remains a 
therapeutic challenge. However, combination therapy with lasers such as 
PDL, Nd:YAG and carbondioxide lasers have shown promising results. 
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PULSED DYE LASER 
 
  Although the first laser used for the treatment of keloids and 
hypertrophic scars was argon laser of the continuous wave type, the 
publication of the phenomenon of ‘selective photothermolysis’ by 
Anderson and Parrish12 in the 1980s created a revolution in the history of 
laser technology. The application of this concept of ‘selective 
photothermolysis’ allowed specific and controlled destruction of a target 
with a very little damage to the surrounding normal tissue.  
 
 This theory brought about the invention of pulsed lasers which were 
highly target – specific and selective, thereby decreasing the amount of 
damage occurring to the surrounding unwanted tissue. 
 
 In the late 80s, the pulsed dye laser with a wavelength of 585 nm 
that is vascular specific (oxyhaemoglobin is the chromophore) became 
very popular and its effectiveness in the treatment of vascular lesions was 
known widely.  
 
Later, a few clinicians started deploying the pulsed dye laser for 
reducing the persistent erythema associated with keloids and hypertrophic 
scars. In 1933, Alster et al. showed that PDL treatment improved the 
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texture of the skin, pliability and bulk of argon laser-induced scars. 
Subsequently, several studies demonstrated a very significant 
improvement of surgical as well as traumatic hypertrophic scars, with a 
couple of sittings with the PDL.83,84,91,92In the early 1990s, it became quite 
evident that PDL could emerge as the most effective treatment with long 
standing improvement of various erythematous keloids and hypertrophic 
scars without any recurrence. 
It was also proved that the keloid sternotomy scars and burn scars 
also respond to the laser therapy with PDL without any recurrence.66,88 
 
Construction of a PDL 
Pulsed dye laser, powered by a flash-lamp, emits a beam of yellow 
light which is pulsed and has a wavelength of 585 nm.93 The lasing or the 
active medium is a fluorescent organic dye that is dissolved in a liquid and 
contained in a transparent cell.94 The chemical structure of the dye, the type 
of solvent, and other additives used determine the lifetime of the device, 
which may be affected, because of the decomposition of the dye or the 
solvent, when exposed to heat.94 The dye that is efficacious and has a 
longer life time is Rhodamine 6G. The transparent chamber housing the 
dye is surrounded by a flash lamp that is able to produce pulse duration of 
450 μs.94 
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The pulse duration of 450 μs is at the lower side of the range of the 
thermal relaxation time of the vasculature of the skin95 which ranges from 
200−3000 μs for vessels with a diameter of 10−40 μm.94 At a wavelength 
of 585 nm and a pulse duration of 450 μs, PDL penetrates to about 0.2 mm 
belowthe epidermis, which can also be increased by increasing the 
wavelength.94 
 
Usage of the first-generation PDLs with smaller spot size, shorter 
pulse durations and wavelengths along with high fluence resulted in very 
high rates of complications, of which, the most common was the 
cosmetically unacceptable post treatment purpura that appears 
immediately and lasted for a week or two.96 
 
Adverse effects of PDL 
a) Post-operative purpura, 
b) Hyper pigmentation or hypopigmentation,  
c) Hypertrophic scarring,  
d) Atrophy 
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The pulsed dye lasers that have been developed more recently, have larger 
spot sizes and longer wavelengths of 590 nm, 595 nm and 600 nm, thereby, 
being able to penetrate to a greater depth. They also have longer pulse 
durations corresponding to the size of the feeding vessel, and provide 
epidermal cooling to ensure a safe delivery of higher fluences without 
complications. Fluences ranging from 3 to 10 J/cm2 are deliveredwith spot 
sizes of 2, 3, 5, 7, or 10 mm and an elliptical spot size of 2 × 7 mm.  
Immediate purpura following PDL with high peak energy and short 
pulse duration is thought to be produced due to a photoacoustic rupture of 
capillary walls resulting in leakage of RBCs into the extravascular tissue.96 
 
PDL with a longer pulse duration attains a lower peak energy, 
resulting in slower application of thermal energy to the blood vessels. This 
in turn, removes or decreases the photoacoustic effect to the capillary 
vessel walls with minimal leakage of red blood cells thereby, resulting in 
‘no purpura’ while maintaining the clinical efficacy.96 
 
 PDL can safely be employed in infants and children.97 It has been 
suggested that multiple and recurrent sittings with PDL should be preferred 
in order to prevent complications in children.97 This was initially used for 
port wine stains, but is now being used extensively for a variety of acquired 
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vascular lesions like pyogenic granulomas, telangiectasias, cherry 
angiomas, venous lake and poikiloderma of civatte.  
 However, the maintenance and servicing of the pulsed dye laser is 
very difficult as the dye and the flash lamp have to be verified at the end 
of each year and need to be replaced if required. The laser machine has to 
be turned on at least once in a day to facilitate the circulation of the dye 
within the machine for a proper functioning. 
 
Mechanism of Action 
 The exact mechanism by which PDL causes regression of keloids 
and hypertrophic scars is not known, however, the plausible theories are 
based on the phenomenon of ‘selective photothermolysis’. Most accepted 
hypothesis is as follows:70 
Light energy from a vascular laser (PDL) 
 
Absorbed by haemoglobin 
 
Heat generation 
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Coagulation necrosis 
 
Decreased microvascular perfusion &tissue hypoxia 
 
Neocollagenesis 
 
Heating of collagen fibers 
 
Dissociation of disulphide bonds 
 
Realignment of collagen fibres 
 
Decreased fibroblast proliferation and reduced deposition of type 3 
collagen 
 
 
Other authors suggest a role of mast cell factors such as histamine, 
interleukins etc. in modifying the metabolism of collagen.66 
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Technique 
 
The procedure of PDL therapy is done on an out-patient basis 
without the need of an admission in the hospital or general/spinal 
anaesthesia as there is very minimal discomfort/burning sensation. 
However, if desired, local anaesthesia can be delivered using a topical 
lidocaine/prilocaine cream under occlusion for 30 to 45 minutes.  
 
Skin should be wiped with a wet gauze prior to the irradiation with 
laser in order to remove dirt or any makeup. If the procedure has to be 
performed over sensitive areas of the body such as fingertips, breast, 
perineum etc, intralesional anaesthetic injections or nerve blocks may be 
of help. Protective eye wear should be worn by the patient, doctor and also 
the others assisting the procedure in the room. 
 
Technically, a series of adjacent, non-overlapping pulses of laser 
should be delivered across the entire area of the scar at each session. The 
procedure needs to be done with a perfectly chosen energy density 
depending on the thickness, location and duration of the scar, keeping in 
mind the patient’s skin type. 
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  If the first treatment session results in a good response, the energy 
density should be kept constant on subsequent sessions. If the response is 
minimal, the fluence has to be increased by 10%. However, if there is post-
operative blistering or crusting, a lower energy density should be chosen 
for the next visit. 
 
 After the procedure, the patient needs to be counselled about 
avoiding unnecessary manipulation of the lased areas. He/she should also 
be advised application of sunscreen, avoidance of sun exposure and use of 
topical antibiotics if necessary. The treated area should be evaluated after 
a period of 6-8 weeks and next session of laser therapy done if required. 
 
 If the treated area develops hyperpigmentation, next treatment 
session should be postponed to avoid the interference of the therapy from 
a competing target (or chromophore), like melanin. Such cases can be 
treated with creams containing hydroquinone to accelerate the fading of 
pigmentation. 
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Hypertrophic scars regress by about 50-80% after a couple of 
treatment sessions. However, keloids or very fibrotic hypertrophic scars 
require more number of sessions with other therapies in combination for a 
good response. 
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  FRACTIONAL CARBON-DIOXIDE LASER 
 
The technology of fractional lasers is an emerging branch for the 
aesthetic improvement of scars, striae, wrinkles and resurfacing. Since the 
1980s, the concept of ‘fractional photothermolysis’ has revolutionized the 
field of laser resurfacing of skin. 
 
             Fractional laser technology is rapidly evolving and becoming 
popular when compared to ablative and non-ablative technology because 
of its safety profile without major side effects, reduced down time and 
efficient clinical outcome. 
 
 The first CO2 gas laser was developed by C. Kumar N. Patel from 
India in 1964 and was operated at Bell Laboratories. It was initially used 
in the industrial field, though, it made its way into the field of medicine by 
1970.98,99 
 
   The carbondioxide laser produced infrared light with a wavelength 
of 10,600 nm and was primarily used for tissue vapourization (water being 
the chromophore/target) and destruction of a variety of cutaneous lesions.11 
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Laser treatment of keloids and hypertrophic scars started with 
carbondioxide, argon and Nd:YAG lasers in the mid 1990s.  
 
Principle of Fractional Photothermolysis  
 
This concept was introduced by Manstein et al.100 in the year 2004 
in a device that emitted light in a pixilated pattern to the skin, creating an 
array of MTZs i.e. microthermal zones and producing thermal injury to the 
skin in tiny microscopic columns.100This process causes thermal ablation 
of epidermal and dermal tissue in microscopic columns that are regularly 
spaced in arrays over a fraction of the surface of the skin, unlike the 
ablative resurfacing which causes a confluent patch of dermal or epidermal 
thermal injury 
 
Fractional photothermolysis, therefore induces thermal alteration of 
skin in fractions or columns, without ablating the intervening areas that 
immediately repopulate the lased area. Different machines provide 
different depth, size and number of MTZs and in the same way, in a single 
machine, by using different settings such as number of stackings and 
fluence. 
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A variety of desired results can be obtained. In each treatment 
session, the formation of zones is limited to only about 15 to 25 percent of 
the lased area. Each zone is about 100 to 160 μ in diameter and about 300 
to 700 μ in depth. The above mentioned measurements for each zone are 
obtained when the energy used is 8-12mJ/MTZ, which is the usual setting 
used when treating the face of the patient.  
 
The most important advantage with this type of machine is that the 
MTZ’s density can be adjusted according to the requirement of the patient, 
which is usually maintained at 2000 MTZs/cm2for every treatment session. 
This density is obtained when only 20% of the surface of the skin is treated. 
Transepidermal elimination is a phenomena where the dermo-epidermal 
debris which forms the MENDs (microscopic epidermal necrotic debris) is 
automatically cleared.101-103 
  
 Following this, there is induction of repair and reepithelialisation 
conducted by the columns of intact skin surrounding the affected skin. 
There is accumulation of the epidermal stem cells and the fibroblast 
derived neocollagenogenesis in the tissue where there was thermal 
ablation, as in ablative laser resurfacing.  
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 The advantage with the non-ablative laser is that there is no 
epidermal ablation, dermal content extrusion even though it works on the 
same principle of production of microthermal zones.  
 
 This minimal downtime in this procedure makes it superior to other 
treatment options. The downtime is reduced as the major portion of the 
skin which is present in between the treated zones remains non-ablated, 
aiding the quick regeneration of the treated skin. These fractions are 
operated upon in each session and after 2 to 6 sittings the therapy is ended. 
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Advantages of fractional lasers: 
a) Suitable for dark skin 
b) Minimal downtime 
c) Reduced postoperative edema and erythema 
d) Reduced dyschromic changes  
 
 The results obtained in the ablative resurfacing are much better when 
compared to the non-ablative or to the fractional. But, due to the minimal 
downtime and quick healing, the latter have become the treatment of choice 
for most of the patients.  
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Ablative Laser Systems 
 
 The field of dermatology has evolved greatly in the last decade but 
the field of laser therapy had the most unprecedented progress. Since the 
last 25 years, the scanned and the pulsed CO2and the erbium:YAG lasers 
were excessively used all over the world. The success of this laser therapy 
for the treatment of  
 
 Atrophic scars  
 Dyschromias 
 Photo-induced facial rhytides 
 Photo-damaged skin  
is well known all over the world. 
 
Continuous wave CO2system was one of the first CO2 lasers used to 
produce large amounts of heat deposition and would cause charring of skin 
due to the enormous delivery and absorption of energy.  
 
The unforeseeable amount of thermal necrosis and the formation of 
scar resulting from these CW lasers interdict the application of this laser 
for facial resurfacing. 
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 With the evolution of the scanned, pulsed and the high energy lasers, 
it has become extremely safe to use these lasers over delicate areas such as 
the face. It is now possible to use the laser to such a precision that it became 
the therapy of choice for the facial resurfacing. These lasers were able to 
produce a limited tissue ablation with minimal coagulative necrosis of the 
structures in the near vicinity. Due to its minimal side effects and ease of 
use, it became the gold standard for facial rejuvenation. 
 
When the patients with photo-damaged or scarred skin were treated 
with this laser, it produced remarkable results in the clinical and 
histopathologic aspect. The remodelling and collagen shrinkage, which 
were most probably the reason for prolonged clinical improvement, 
required 1 or 2 additional passes in comparison to the epidermal ablation 
which occurred after a single pass of the CO2laser therapy.  
 
The dissociation of the interpeptide bonds occurs when the skin 
temperature increases to more than 62°C, as a result, there is a 
conformational change within the collagen structure that reduces the size 
of the moiety by almost two thirds of its normal length. The 
pathomechanism of prolonged neocollagenogenesis and remodelling after 
the therapy is not clear. However, it is assumed that this effect is generated 
due to the thermal desiccation along with the shrinking collagen. As there 
is exaggerated expression of actin post treatment, there is the scaffold 
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formation due to the shrinkage, which acts as a support for the deposition 
and remodelling of the wound. There is around 50% improvement in the 
atrophic scar depth, rhytide severity and skin tone in patients treated with 
CO2 laser. But, because of its high postoperative morbidity, it is not usually 
considered. 
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LONG–PULSE Nd:YAG LASER 
 The operation of the first Nd:YAG Laser was demonstrated by 
Joseph E. Geusic et al.105 in 1964 and its high emission was proposed to be 
useful in coagulating large blood vessels.106 
 
Long pulse Nd:YAG has now become a point of interest in the 
treatment of keloids as it has shown to exert its effects on the 
microvasculature of the dermis, as well as, metalloproteinase. 
 
Rationale for choosing Nd:YAG  
a) Dual mode of action: On both collagen and vessels. 
b) Non-invasiveness 
c) Good tolerability 
d) Safety profile 
Although PDL was found to be very effective in the treatment of 
cutaneous vascular diseases, it had a disadvantage of not being able to 
penetrate beyond the papillary dermis and this is where, long pulse 
Nd:YAG (neodymium-yttrium-aluminium-garnet) with a wavelength of 
1064 nm came into light as it can penetrate till the reticular dermis.   
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Therefore, its application in deep vascular diseases such as keloids 
and hypertrophic scars has been increasing. 
 
It has been thought that this laser acts by exerting a suppression of 
neovascularisation in these scars which have a characteristic overgrowth 
of blood vessels resulting in the presence of collagen and nerve fibers in 
the reticular dermis. 
Mechanism of Action 
Heat generation 
 
Increased vascular permeability 
 
Increased production matrix metalloproteinase-13 
 
Decomposition of collagen fiber fascicle 
 
Keloid regression 
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Sherman et al.107 reported an in vitro study in the year 1988, which 
demonstrated a reduction in the production of collagen induced by 
Nd:YAG laser. Also, a decrease in the erythema and induration was 
documented by them. 
 
It is said that the limited depth of penetration caused by the yellow 
light emitted by the pulsed dye laser leads to resistance to further therapy 
with PDL due to the absorption and scattering in the epidermis and dermis 
(depth of about 1-2mm).107,108  
 
 Therefore, the deeper blood vessels can be specifically treated using 
Nd:YAG laser with a wavelength of 1064 nm. Owing to the deeper 
penetration and lower absorption by haemoglobin, the Nd:YAG laser 
(1064 nm) has become a better option in the treatment of deep vascular 
lesions than the conventionally used shorter wavelength sources. 
 
Pathological scar development may also be influenced by 
interactions between mechanical pulling force, inflammation around the 
keloid, production of collagen and angiogenesis which suggests that 1064 
nm Nd:YAG laser therapy may be efficacious in the treatment of 
pathological scars as it could minimise the vascularity of these scars.109,110 
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        This decreased vascularity may reduce the levels of cytokines or 
growth factors in the tissue, which, in turn, promote deposition of collagen.  
 
      However, the laser might not be efficacious if the scars continue to 
be subjected to strong mechanical forces at and around the wound site. 
 
Abergel et al. have demonstrated a photobiological effect on the 
metabolism of collagen using the Nd:YAG laser.76 
 
 It was observed that there was a selective inhibition of the 
production of collagen in the human dermal fibroblasts derived from tissue 
cultures after the delivery of only 1.1 x 103 J/cm2 of Nd:YAG laser. 
 
Cohen and Diegelmann suggested that Nd:YAG has a unique ability 
of selectively suppressing the collagen synthesis without affecting the 
replication of DNA and cell viability.111 
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Adverse effects 
a) Post inflammatory hyperpigmentation 
b) Post inflammatory hypopigmentation 
c) Thermal injury/burns 
d) Infection 
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MATERIALS AND METHODS 
 
Study design 
 Hospital based observational study 
 
Period of study 
This study was conducted over a period of 2 years in patients with 
keloids after obtaining approval from the Institutional Human Ethics 
Committee.  
 
Research subjects 
The study was carried out on patients attending the out-patient 
department of Dermatology, Venereology and Leprosy, PSG IMSR, 
Coimbatore. 
Sample size 
15 patients 
Inclusion criteria 
 15 patients above 15 years of age with keloids were included in the 
study. 
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Exclusion criteria 
1. Patients below 15 years of age,  
2. Pregnant and lactating females, and  
3. Patients with history of isotretinoin use in the last 6 months. 
 
Consent 
Written and informed consent (both in English and local language) 
was obtained from each patient prior to starting the treatment and taking 
photographs. 
 
Photographic documentation 
Photographs of every keloid included in the study were taken at 
baseline and before each session of LASER, using a DSLR Nikon D5100. 
 
Procedure 
After taking photographs, patients were locally anaesthetised by 
topical application of a eutectic mixture of lidocaine and prilocaine, over 
the keloid to be treated, under occlusion for 1 hour. The cream was then, 
wiped off with a wet gauge and the area to be lased was cooled with 
icepacks in order to prevent unnecessary thermal injury and discomfort. 
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     Protective eye wear was provided to the patient, treating doctor and 
all the personnel assisting the procedure.  
(Picture 1& 2) 
Fractional CO2 laser (Lumenis) was delivered. After 5 mins of 
cooling of the lesion, long pulsed Nd:YAG & pulsed dye laser using the 
Cynosure Cynergy Multiplex was delivered.  
(Pictures 3 & 4) 
 
Laser parameters 
 
Fractional CO2 LASER was delivered as follows: 
Initial energy of 10mJ was delivered with increments of 5mJ at each 
sitting. Five minutes after the delivery of fractional CO2, Cynosure 
Cynergy multiplex (long pulse Nd:YAG and pulsed dye LASER) was 
delivered at a PDL fluence of 4J/cm2 in the 1st sitting with increments of 
1J/cm2 during each sitting, while keeping the fluence of YAG constant at 
20J/cm2.  
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Post-procedure care 
 The lased area was again cooled,  
 Patient was counselled about adequate photo-protection and the 
utmost necessity of sunscreen application. 
 Topical steroid was applied immediately post-procedure to reduce 
the inflammation 
 
Laser Sessions 
 Every patient underwent 5 sittings of the treatment with fractional 
CO2, PDL and long pulse Nd:YAG lasers at intervals of 4 weeks. 
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Adverse Events 
a) All patients tolerated the procedure well. 
b) No complications such as hypo or hyperpigmentation, ulceration, or 
infection were observed during the course of the study. 
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RESULTS 
 
Out of the 15 patients included in the study, 11 patients completed 
the study. 4 patients discontinued the study and were lost for follow-up. 
Clinical improvement was monitored based on a VAS (visual analogue 
scale) graded by 3 blinded observers after assessing clinical photographs. 
The parameters analysed using the VAS were the colour, size and aesthetic 
impression.  
          A score of 0 for ‘no improvement, 1 for ‘mild improvement’(<25%), 
2 for ‘moderate improvement’(26%-50%), 3 for ‘good 
improvement’(51%-75%) and 4 for ‘excellent improvement’(76%-100%) 
was given.  
 
0 0% No improvement 
1 <25% Mild improvement 
2 26-50% Moderate improvement 
3 51-75% Good improvement 
4 76-100% Excellent improvement 
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VAS Scale used 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
75 % 
50 % 
25 % 
100 % 
0 % 
Score – 1,   
Mild improvement 
Score – 0,   
No improvement 
Score – 2,   
Moderate improvement 
Score – 4,   
Excellent improvement 
Score –3,   
Good improvement 
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Analysis of the scoring 
 The mean of the scores given for all the 3 parameters (size, colour, 
aesthetic impression) by each observer for each patient was calculated and 
recorded. 
 
 Then, the mean of the mean scores given by all the 3 observers was 
calculated and recorded as ‘overall improvement’. 
 
 Also, the mean of scores given for each parameter for each patient 
by all the 3 observers was calculated, aiding us to assess the improvement 
of individual parameters in each patient. 
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Scoring by observer 1 
 
 
S.No. of 
Patients 
Size Color 
Aesthetic 
impression 
Mean score of 
3 parameters 
1 3 3 3 3 
2 1 1 1 1 
3 1 1 1 1 
4 2 2 2 2 
5 3 3 3 3 
6 0 0 0 0 
7 1 1 1 1 
8 2 2 2 2 
9 0 0 0 0 
10 2 2 2 2 
11 4 4 4 4 
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Scoring by observer 2 
S.No. of 
Patients 
Size Color 
Aesthetic 
impression 
Mean score of 
3 parameters 
1 3 2 3 2.66 
2 3 2 2 2.33 
3 0 0 0 0 
4 3 2 3 2.66 
5 1 1 1 1 
6 0 0 0 0 
7 0 0 0 0 
8 2 1 2 1.66 
9 0 0 0 0 
10 0 0 0 0 
11 3 3 3 3 
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Scoring by observer 3 
 
S.No. of 
Patients 
Size Color 
Aesthetic 
impression 
Mean score of 
3 parameters 
1 2 2 2 2 
2 3 2 2 2.33 
3 2 2 2 2 
4 3 2 3 2.66 
5 2 2 3 2.33 
6 1 1 1 1 
7 0 0 0 0 
8 2 2 3 2.33 
9 0 0 0 0 
10 2 2 2 2 
11 4 3 4 3.66 
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Mean of the scores given by 3 observers (‘Overall improvement’) 
S No. of 
Patients 
Mean 
score by 
observer 
1 
Mean 
score by 
observer 
2 
Mean 
score by 
observer 
3 
Mean 
of 3 
mean 
scores 
Rounded 
to 
Interpretation 
of ‘overall 
improvement’ 
1 3 2.66 2 2.55 3 Good 
2 1 2.33 2.33 1.88 2 Moderate 
3 1 0 2 1 1 Mild 
4 2 2.66 2.66 2.44 2 Moderate 
5 3 1 2.33 2.11 2 Moderate 
6 0 0 1 0.33 0 No 
7 1 0 0 0.33 0 No 
8 2 1.66 2.33 1.99 2 Moderate 
9 0 0 0 0 0 No 
10 2 0 2 1.33 1 Mild 
11 4 3 3.66 3.55 4 Excellent 
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Out of the 11 patients, 1 patient had excellent overall improvement 
(9%), 1 patient had good overall improvement (9%), 4 patients had 
moderate overall improvement (37%), 2 patients had mild overall 
improvement (18%) and 3 had no improvement (27%). 
 
 
 
 
Excellent (1 patient)
9%
Good (1 patient)
9%
Moderate (4 
patients)
37%
Mild (2 patients)
18%
No improvement (3 
patients)
27%
OVERALL IMPROVEMENT
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Mean of the scores given by 3 observers for ‘Size’ 
 
S.No. of 
Patients 
Score for 
‘size’ by 
observer 
1 
Score for 
‘size’ by 
observer 2 
Score for 
‘size’ by 
observer 3 
Mean of 3 
scores for 
‘size’ 
Rounded 
to 
Interpretation 
of 
improvement 
in ‘size’ 
1 3 3 2 2.66 3 Good 
2 1 3 3 2.33 2 Moderate 
3 1 0 2 1 1 Mild 
4 2 3 3 2.66 3 Good 
5 3 1 2 2 2 Moderate 
6 0 0 1 0.33 0 No 
7 1 0 0 0.33 0 No 
8 2 2 2 2 2 Moderate 
9 0 0 0 0 0 No 
10 2 0 2 1.33 1 Mild 
11 4 3 4 3.66 4 Excellent 
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On analysing the size, we have observed that, out of the 11 patients, 
improvement in size was excellent in 1 patient (9%), good in 2 patients 
(18%), moderate in 3 patients (28%), mild in 2 patients (18%) and nil in 3 
patients (27%). 
Excellent (1 
patient)
9%
Good (2 patients)
18%
Moderate (3 
patients)
28%
Mild (2 patients)
18%
No improvement 
(3 patients)
27%
IMPROVEMENT IN SIZE
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Mean of the scores given by 3 observers for ‘Color’ 
 
 
 
 
S.No. of 
Patients 
 
Score for 
‘color’ by 
observer 
1 
 
Score for 
‘color’ by 
observer 
2 
 
Score for 
‘color’ by 
observer 
3 
 
Mean of 
3 scores 
for 
‘color’ 
 
 
Rounded 
to 
 
Interpretation 
of 
improvement 
in ‘color’ 
1 3 2 2 2.33 2 Moderate 
2 1 2 2 1.66 2 Moderate 
3 1 0 2 1 1 Mild 
4 2 2 2 2 2 Moderate 
5 3 1 2 2 2 Moderate 
6 0 0 1 0.33 0 No 
7 1 0 0 0.33 0 No 
8 2 1 2 1.66 2 Moderate 
9 0 0 0 0 0 No 
10 2 0 2 1.33 1 Mild 
11 4 3 3 3.33 3 Good 
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Evaluation of the refinement in color revealed that no patient had 
excellent improvement, 1 patient had good improvement (9%), 5 patients 
had moderate improvement (46%), 2 patients had mild improvement (18%) 
and 3 patients had no improvement (27%). 
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0%
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Mean of scores given by 3 observers for ‘Aesthetic impression’ 
 
S.No. of 
Patients 
Score by 
observer 
1 
Score by 
observer 
2 
Score by 
observer 
3 
Mean of 3 
scores for 
‘Aesthetic 
impression’ 
Rounded 
to 
Interpretation of 
improvement in 
‘aesthetic 
impression’ 
1 3 3 2 2.66 3 Good 
2 1 2 2 1.66 2 Moderate 
3 1 0 2 1 1 Mild 
4 2 3 3 2.66 3 Good 
5 3 1 3 2.33 2 Moderate 
6 0 0 1 0.33 0 No 
7 1 0 0 0.33 0 No 
8 2 2 3 2.33 2 Moderate 
9 0 0 0 0 0 No 
10 2 0 2 1.33 1 Mild 
11 4 3 4 3.66 4 Excellent 
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On the analysis of ‘aesthetic impression’, it was found that, out of 
the 11 patients, improvement in aesthetics was excellent in 1 patient (9%), 
good in 2 patients (18%), moderate in 3 patients (28%), mild in 2 patients 
(18%) and nil in 3 patients (27%). 
  
Excellent (1 
patient)
9%
Good (2 patients)
18%
Moderate (3 
patients)
28%
Mild (2 patients)
18%
No improvement 
(3 patients)
27%
IMPROVEMENT IN AESTHETIC IMPRESSION
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DISCUSSION 
 
Keloids are abnormal wound responses characterised by excessive 
deposition of collagen and glycoprotein. They occur in predisposed 
individuals as a result of connective tissue response to trauma or may 
sometimes, have a spontaneous development.  
 
It has been investigated that the activity of fibroblasts, various 
growth factors, components of extracellular matrix, cytokines and immune 
response portray the cellular basis of exaggerated fibrogenesis leading to 
the formation of a keloid. 
 
They are both aesthetically and symptomatically distressing for most 
of the patients. Keloidal scars may cause symptoms like pain, pruritus, 
restriction of movements and also aesthetic disfigurement leading to a 
significant amount of morbidity. 
 
 They give rise to both functional and aesthetic distress to the patient 
and have always been a therapeutic challenge, despite the innumerable 
modalities of treatment. Conventional methods for the treatment of keloids 
include surgical excision, dermabrasion, grafting, radiation, pressure 
therapy, silicone gel sheeting and intralesional corticosteroids.2,3 
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 There has been a magnificent advancement in the field of lasers in 
dermatology over the last three decades. It is quite well-known that this 
revolution has changed the face of aesthetics and dermato-medicine. 
 
Lasers have been in use for a variety of skin conditions like 
pigmented lesions, vascular anomalies, tattoos, hirsutism, keloids and 
hypertrophic scars, and also for skin resurfacing. They have become a well-
known treatment modality for the management of keloids in recent years.  
 
There are reports of keloid management with pulsed dye laser, 
fractional CO2 and Nd:YAG laser individually and also in combination of 
CO2 with PDL and CO2 with Nd:YAG.  
 
   Here, we discuss a combination of all the 3 LASERs as therapy for 
keloids. A total of 15 patients above 15 years of age, with keloids were 
included in our study. If a patient presented with more than one keloid, 
only one keloid from each patient was considered for our study. 
 
In a study conducted by Kono et al.,112 19 hypertrophic scars were 
irradiated with a pulsed dye laser which demonstrated that 16 lesions 
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(84%) showed significant flattening of the scar and reduction in erythema. 
Therefore, he suggested that treatment of scars with pulsed dye laser can 
help to reduce the erythema and size very effectively. 
 
In our study, where we used a combination of 3 lasers, it was found 
that, out of 11 lesions, 8 lesions (73%) showed improvement in size and 
erythema/color which was almost in accordance with the study done by 
Kono et al.112 
 
In 2004, Chan et al.82 treated 36 scars in 27 patients with 585 nm – 
PDL and 66% reported clinical improvement which is slightly less than 
that of our study which showed improvement in 72% of patients. 
 
   Another study done by Nouri et al.87 in 2003, revealed that all the 12 
post operative scars treated with 3 sessions of pulsed dye laser (585nm) 
showed significant overall improvement and enhanced cosmetic 
appearance. However, in our study, improvement in aesthetic impression 
was seen only in 8 (73%) out of 11 patients.    
 
 Alster4, in 2003, treated 22 hypertrophic scars using PDL and found 
that there was a very significant clinical and histologic enhancement. We 
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cannot compare our study with the above as we have not done a histologic 
evaluation. 
 
Paquet et al.68 treated 11 keloids with PDL in 2001 and proposed that 
there was no significant difference in the size and also in the refinement of 
erythema which is contradiction to the study done by us. 
 
Connell and Harland108 managed 10 recalcitrant keloids in 10 
patients with a combination of PDL and intralesional steroid and reported 
that 7 of them had good improvement in the size and erythema. They have 
also stated that the results of this combined therapy are not only adjunctive, 
but also summative. In our study, we have not combined PDL with any 
other adjunctive therapy. 
 
 Shakespeare et al.114 conducted a study with PDL on hypertrophic 
scars in 11 patients and showed that there was significant improvement in 
all the cases. In our study, there was significant improvement only in 8 out 
of 11 cases.  
 
Alster and Nanni,88 treated 40 hypertrophic scars with pulsed dye 
laser and found that all the lesions had reduction in the erythema with 
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improvement in the texture and pliability. In our study, reduction in 
erythema was seen only in 8 out of 11 patients. 
 
In another study carried out by Dierickx et al.83, 15 patients were 
treated with PDL and it was found that all the scars showed significant 
reduction in the scar erythema. 
 
Goldman and Fitzpatrick84 conducted a study using PDL on 48 
patients with hypertrophic scars and demonstrated that all the scars 
resolved completely. However, in our study, only 1 out of 11 patients 
showed complete resolution. 
 
 A study done by Alster and Williams66 in 1995 on keloid sternotomy 
scars using PDL showedsignificant improvement in erythema, scar size 
and pruritus, the results of which are in a close agreement with the study 
conducted by us. 
 
Several studies using CO2 laser were carried out to prove its efficacy 
in the treatment of keloids. Norris72 in 1991, Apfelberg et al.116 in 1989, 
Stern &Lucente71 also in the year 1989 conducted studies to assess the 
efficacy of CO2 laser on keloids but failed to prove promising results. 
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 However, a study conducted by Alster et al.115 in 20 patients with 
hypertrophic scars proved to be effective when the CO2 laser was used in 
combination with PDL. 
 
 Kumar et al.113 treated 17 keloids with Nd:YAG laser and 
demonstrated that 10 lesions (58.8%) completely resolved and 7 lesions 
(41.2%) showed only partial resolution. But our study demonstrated 
complete resolution only in 1 keloid (9.09%) and partial resolution in 7 
keloids (63.64%). 
 
 Sherman & Rosenfeld,107 in the year 1988 irradiated 17 keloids with 
Nd:YAG and found promising results with all the keloids. Similarly, 
Abergel et al.117 conducted a study in 8 patients with keloids using 
Nd:YAG laser and demonstrated good results. 
 
Several laser sessions are advised for obtaining promising response 
but lower fluences are suggested for the avoidance of adverse effects in 
patients with a higher melanin content in the skin. 
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CONCLUSION 
 
LASERs are now being used to enhance keloids and hypertrophic 
scars. After their introduction for keloids and hypertrophic scars by 
Apfelberg et al.64 and Castro et al.118 in the 1980s, the field of lasers has 
been evolving magnificently and several lasers with varied wavelengths 
have been studied, although making it very difficult for a clinician to assess 
the efficacy of each. 
 
Lasers used either singly or in combination may be effective to a 
varying degree in the treatment of keloids. We plan to conduct studies 
combining all other modes of treatments along with LASERs to determine 
if better results can be achieved. 
 
Limitations 
 The small sample size. 
 The number of LASER sessions was limited to 5. 
 The other modalities of treatment were avoided in order to assess the 
efficacy of LASERs alone. 
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CONSENT FORMS 
  
 
 
 
Informed Consent 
 
We Dr. Ashwini Annabathula, Dr.Shanmuga Sekar and Dr. C.R.Srinivas 
of the PSG Institute of Medical Sciences and Research (PSG IMSR), are 
carrying out a study titled :  
Fractional CO2, Long Pulse Nd:YAG and Pulsed Dye Laser in the 
Management of Keloids. 
Under the aegis of the Department Of Dermatology, PSG IMSR. 
The objectives of this study are: 
- To assess the efficacy of Fractional CO2 , Long Pulse Nd:YAG 
and Pulsed Dye Laser in the management of Hypertrophic Scars 
and Keloids 
The goal of this study is: To achieve reduction in the size of keloids and 
hypertrophic scars  
Sample size: 15 
Respondents are (population group & age group): 15 years and older men 
and women who present with Keloids to the Dermatology OPD 
Location: Coimbatore, Tamil Nadu. 
We request you to kindly cooperate with us in this study. We propose 
collect background information and other relevant details related to this 
study. We will be carrying out (strike off items that are not applicable): 
Initial interview (specify approximate duration): _____min. 
Health education sessions:  
            No. of sessions:  N/A 
            Approximate duration of each session: N/A min.  
Clinical examination (specify details and purpose): The lesions to be 
treated will be examined prior to treatment. 
Blood sample collection:   N/A Specify purpose, discomfort likely to be 
felt and side effects, if any: Mild erythema and irritation 
 
 
Final interview (specify approximate duration):  N/A min. 
If photograph is taken, purpose:   To compare the before, after, and follow-
up pictures of the treated lesions for assessment of improvement 
Benefits from this study, if any: New modality of treatment in the 
management of Keloids. 
If you are uncomfortable in answering any of our questions during the 
course of the interview/ blood sample collection, you have the right to 
withdraw from the interview / study at any time. You will NOT be paid 
any remuneration for the time you spend with us for this interview / study. 
The information provided by you will be kept in strict confidence. Under 
no circumstances shall we reveal the identity of the respondent or their 
families to anyone. The information that we collect shall be used for 
approved research purposes only. 
 
Consent: The above information regarding the study, has been read by me/ 
read to me, and has been explained to me by the investigators from the PSG 
IMS&R. Having understood the same, I hereby give my consent to them 
to interview me. I am affixing my signature/left thumb impression to 
indicate my consent and willingness to cooperate in this study. 
 
Respondent ID: _________. 
 
 
Signature / Left thumb impression of the Respondent                        
 
 
Signature of the Investigator   
 
 
Signature of the witness 
  
 
 
Xg;gjy; gotk; 
njjp          
m!;tpdp md;dhgj;Jy;yh Mfpa ehd;  PSG kUj;Jtf;fy;Y}hpapd; 
gpuhf;#dy;   CO2  nyrh;/  yh'; gy;!; vd;.o.ahf; nyrh; kw;Wk; gp.o.vy; 
nyrh; \yk; tsh; tLtpid mfw;Wjy; gw;wp Ma;t[j;jpwd; nkw; bfhs;s 
cs;nsd;. 
  
vd; Ma;t[ tHpfhl;o   :   kU.r. rz;Kfnrfh; 
 
Ma;t[ nkw;bfhs;tjw;fhd mog;gil :   
tsh;tL  njhypy; fl;oj; jGk;ig cUthf;Fk;.  mj;jGk;ig 
Fzg;gLj;j gy;ntW rpfpr;ir ,Ug;gpDk; KGikahf Fzg;gLj;Jk; 
kUj;Jt Kiwfs; kpft[k; Fiwt[.  ,jd; \yk; tsh;tLf;fhd 
g[jpabjhU rpfpr;ir Kiwgw;wp Ma;t[j;jpwd; nkw;bfhs;fpnwd;. 
 
Ma;tpd; nehf;fk; :   tsh;tLit Fzg;gLj;Jjy; 
  
Ma;t[ nkw;bfhs;Sk; ,lk; :  gp.v!;.$p kUj;Jtkid/  
         njhy; ghy;tpid kw;Wk; bjhGneha; 
Jiw 
 
ghpnrhjidf;F cl;gLj;jg;gl;lth;fspd; vz;zpf;if  : 15 
taJ tuk;g[   :   15 tajpw;F nky; 
,lk;   :  njhy;/ ghy;tpid kw;Wk; bjhGneha;Jiw 
    gp.v!;.$p kUj;Jtkid/ nfhak;g[j;J}h; 
 
 
,e;j Ma;t[f;F v';fSf;F xj;JiHg;igj; jUkhW j';fisf; 
nfl;Lf; bfhs;fpnwhk;.  nkYk;  ,e;j Ma;t[f;Fj; njitahd jfty;fs; 
c';fsplkpUe;J bgw;Wf; bfhs;sg;gLk;. 
 
cly; ghpnrhjid :  nrhjidf;F cl;gLj;jg;gLk; gFjpia 
ghpnrhjpj;jy; 
 
 
ghpnrhjidapd; nghJ Vw;gLk;  gf;ftpist[fs; njhy;  : rpte;Jnghjy;/ 
vhpr;ry; 
g[ifg;glk; vLf;fg;gl;ljh> mjd; nehf;fk; : 
 ghpnrhjidf;F Kd;g[k;/ gpd;g[k; cs;s khw;wj;ij xg;gpl 
 
,e;j Ma;tpy; g';nfw;f xg;g[f; bfhs;Stjhy; ve;jtpjkhd 
gyDk; c';fSf;F fpilf;fhJ.  ve;j neuj;jpy; ntz;LkhdhYk; 
Ma;tpypUe;J tpyfpf; bfhs;Sk; chpik c';fSf;F cz;L. 
Ma;tpypUe;J tpyfpf; bfhs;tjhy; c';fSf;F mspf;fg;gLk; 
rpfpr;irapy; ve;j tpj khw;wKk; ,Uf;fhJ. 
 
,e;j Muha;r;rpf;fhf c';fsplk; rpy nfs;tpfs; nfl;fg;gLk;  
 
nkYk; ,e;j Ma;tpy; g';F bfhs;tJ c';fs; brhe;j tpUg;gk;.  
,jpy; ve;j  tpjf; fl;lhaKk; ,y;iy.  eP';fs; tpUg;gg;gl;lhy; ,e;j 
Ma;tpd; Kot[fs; c';fSf;Fj; bjhpag; gLj;jg;gLk;. 
 
Ma;thshpd; ifbahg;gk; : 
njjp  : 
 
Ma;t[f;Fl;gLgthpd; xg;g[jy; 
ehd; ,e;j Muha;r;rpapd; nehf;fk; kw;Wk; mjd; gad;ghl;oidg; 
gw;wp bjspthft[k; tpsf;fkhft[k; bjhpag;gLj;jg;gl;Ls;nsd;.  ,e;j 
Muha;r;rpay; g';F bfhs;st[k; ,e;j Muha;r;rpapd; kUj;Jt hPjpahd 
Fwpg;g[fis tUk; fhyj;jpYk; cgnahfg;gLj;jpf; bfhs;st[k; KG 
kdJld; rk;kjpf;fpnwd;. 
 
Ma;t[f;Fl;gLgthpd; bgah;/ Kfthp : : 
    ifbahg;gk;  : 
     njjp  : 
 
 
 
 
 
 
 
 
 
 
 
PROFORMA  
 
 
VARIABLES RECORDED 
 
 
Name:                                                Age:                                     OP No. 
 
Gender:                                             Occupation:  
 
Duration of the lesion/s: 
 
History of previous treatment: 
 
History of trauma/acne preceding the development of lesion: 
 
Family History of Keloids:        Y/N 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
 
MASTER CHART 
S. No. 
of 
Patients 
Scoring by observer 1 Scoring by observer 2 Scoring by observer 3 Overall 
Improvement 
(Mean of the mean 
scores by all the 
observers) 
Overall 
Improvement 
(Score rounded 
to) 
Interpretation of 
"Overall 
Improvement"  
Size 
 
Color 
 
Aesthetic 
Impression 
Mean score 
of 3 
parameters 
 
Size 
 
Color 
 
Aesthetic 
Impression 
Mean score of 
3 parameters 
 
Size 
 
Color 
 
Aesthetic 
Impression 
Mean score of 
3 parameters 
1 3 3 3 3 3 2 3 2.66 2 2 2 2 2.55 3 Good 
2 1 1 1 1 3 2 2 2.33 3 2 2 2.33 1.88 2 Moderate 
3 1 1 1 1 0 0 0 0 2 2 2 2 1 1 Mild 
4 2 2 2 2 3 2 3 2.66 3 2 3 2.66 2.44 2 Moderate 
5 3 3 3 3 1 1 1 1 2 2 3 2.33 2.11 2 Moderate 
6 0 0 0 0 0 0 0 0 1 1 1 1 0.33 0 No 
7 1 1 1 1 0 0 0 0 0 0 0 0 0.33 0 No 
8 2 2 2 2 2 1 2 1.66 2 2 3 2.33 1.99 2 Moderate 
9 0 0 0 0 0 0 0 0 0 0 0 0 0 0 No 
10 2 2 2 2 0 0 0 0 2 2 2 2 1.33 1 Mild 
11 4 4 4 4 3 3 3 3 4 3 4 3.66 3.55 4 Excellent 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
  
 ABBREVIATIONS 
 
LASER Light Amplification by Stimulated Emission of Radiation 
Nd:YAG Neodymium-doped yttrium aluminium garnet 
PDL Pulsed dye LASER 
CW Continuous wave 
Q-Switched Quality switched 
TGF β Transforming Growth Factor β 
IGF Insulin-like Growth Factor 
bFGF Basic Fibroblast Growth Factor 
 
 
